And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is notably modest this time around. We plan to catch up on a thick pile of reading, take a few naps, and perhaps binge-watch a show on the telly, a rare indulgence. And what about you? The holiday season is fast approaching, but there is still time to make getaway plans. This is also an opportunity to stimulate the economy and purchase some gifts. You might consider a year-end charitable donation (but do try to avoid those that serve as piggy banks for their namesakes). Or you could simply take stock of life, such as it is. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.

House Democrats passed sweeping legislation to lower prescription drug prices, marking the latest volley in a health care debate that has animated progressives, Republican lawmakers, drug makers, and the Trump administration all year, STAT explains. But the high-stakes showdown over drug prices is far from over. President Trump has vowed to veto the bill, which passed on a 230-192 vote, largely along party lines. And the Republican-controlled Senate is still considering a separate, less aggressive bipartisan drug pricing package.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy